Nusinersen (Spinraza), an antisense oligonucleotide, was recently approved by the United States Food and Drug Administration (FDA) to treat spinal muscular atrophy (SMA), a rare and often fatal ...

Researchers compiled data from studies of oral Evrysdi (risdiplam), Spinraza (nusinersen), and Zolgensma (onasemnogene abeparvovec), finding evidence that risdiplam may be a favorable alternative ...

Cost-effectiveness body NICE has rejected Biogen’s Spinraza (nusinersen) therapy for the rare genetic muscle wasting disease spinal muscular atrophy (SMA) because of its high cost – but is in ...

Discover comprehensive details about Nusinersen, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated ...

What are the clinical circumstances under which it would be appropriate for an individual to continue to have treatment with risdiplam (or nusinersen) after treatment with onasemnogene abeparvovec or ...

A wearable robotic device called HAL improved walking ability for SMA patients who also received Spinraza (nusinersen), a ...